Myeloma Trial, Recruiting NCT07559799 Sponsor: iOMEDICO AG Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT07559799
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have multiple myeloma (a type of blood cancer) that has come back or stopped responding to treatment
  • You have already been treated with at least three different types of cancer treatments: a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody therapy (confirm with trial site if unsure which treatments count)
  • Your cancer came back or got worse after your most recent treatment
  • Your doctor has already decided that you should receive a specific combination treatment called melflufen (Pepaxti®) and dexamethasone as your fourth or later round of treatment
  • You are 18 years old or older
  • You are able to give your written agreement to take part in the trial
  • The decision to join this study was made before you were officially enrolled in it
  • You may still be able to join if you received your first dose of melflufen and dexamethasone within roughly the last 6 weeks, as long as you have not yet had a second dose or had your treatment response checked

Who may not be able to join:

  • You are currently taking part in another clinical trial that involves a specific treatment or procedure (note: being in a follow-up stage of another trial may be acceptable)
  • You are not able to give your own informed consent to participate
  • You have a medical reason why you should not take melflufen (Pepaxti®) and dexamethasone, based on the official prescribing guidelines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 761 / 15 242-0

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
iOMEDICO AG
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
30 August 2029

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Disease control rate (DCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov